Allergan's Assets Could Diversify Pfizer's Neurology Portfolio
This article was originally published in Scrip
If Pfizer Inc. were to buy Allergan plc – or vice versa – the merged companies would have a large and actually quite diverse portfolio of drugs for central nervous system (CNS) diseases and conditions.
You may also be interested in...
Allergan PLC has $27.6m in cash after closing the $40.5bn sale of its generics business to Teva Pharmaceutical Industries Ltd. and paying down $9.3bn debt, but the company will rely on blockbuster sales gains and recent launches for revenue and earnings growth, not a big acquisition.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.